Core Insights - The introduction of PD-1 inhibitors in 2014 marked a significant turning point in the fight against cancer, with Bristol-Myers Squibb's Opdivo and Merck's Keytruda leading the charge in immunotherapy [1][3] - The competition between Opdivo and Keytruda has evolved over the years, with Keytruda ultimately becoming the top-selling drug globally by 2024 [21][22] Historical Context - The history of cancer immunotherapy began with William Coley's discovery in the late 19th century, which was followed by a long period of stagnation until the late 20th century when key immune cells were identified [4] - The discoveries of James Allison and Tasuku Honjo regarding CTLA-4 and PD-1, respectively, laid the groundwork for the development of PD-1 inhibitors [5][10] Drug Development - Opdivo was developed with strong backing from Bristol-Myers Squibb after acquiring Medarex in 2009, leading to its approval in Japan in 2014 [12] - Keytruda's development faced initial setbacks but was revitalized by Merck's strategic decision to conduct an unprecedented "super I phase" trial, leading to its approval shortly after Opdivo [14][15][16] Market Dynamics - In 2016, a critical competition occurred between Opdivo and Keytruda in the non-small cell lung cancer (NSCLC) market, which is the largest segment in oncology [17] - BMS's failure in the CheckMate-026 trial led to a significant drop in Opdivo's market position, while Merck's more selective approach in the KEYNOTE-024 trial resulted in Keytruda's success [18][19][20] Sales Performance - By 2024, Keytruda's sales reached $29.5 billion, marking an 18% increase and solidifying its position as the top-selling drug globally [21] - Opdivo, while still a major player, saw its sales decline but remained above the $10 billion mark, maintaining its status as a heavyweight in the market [22][23] Competitive Landscape - The global PD-1 inhibitor market is highly competitive, with 527 candidates in development as of early 2025, including 20 approved drugs [26][29] - In China, the market is characterized by intense competition among local manufacturers, with significant price reductions due to national healthcare negotiations [30][31] Future Outlook - Keytruda's core patent is expected to expire in 2028, potentially leading to a significant drop in sales as biosimilars enter the market [32] - A new challenger, Ivonescimab, has shown superior efficacy compared to Keytruda in clinical trials, indicating a shift towards dual-target therapies in cancer treatment [33][35]

CAR-T疗法作为肿瘤免疫治疗的重要突破，已在血液肿瘤中展现出显著疗效。其核心在于通过基因工程 改造患者自身的T细胞，使其表达嵌合抗原受体（CAR）。这种受体如同"智能导弹"的制导系统，能特 异识别肿瘤细胞表面的抗原，从而引导T细胞精准杀伤癌细胞。然而，该疗法仍面临挑战：一方面，过 度活跃的CAR-T细胞可能引发危及生命的细胞因子释放综合征（CRS）或神经毒性等严重副作用；另一 方面，CAR-T细胞在持续抗原刺激下易发生功能耗竭，导致疗效下降或复发。因此，开发能够按需调控 CAR-T细胞活性的"安全阀"技术，一直是该领域的关键研究方向。 此次研究引入了一种简单且临床上切实可行的方法，通过远程控制已临床使用的癌症药物维奈托克拉 斯，可逆地降低CAR-T细胞激活。遥控不会触发CAR-T细胞的自毁，而是促使它们脱离并从癌变目标上 脱落。 经典的CAR细胞拥有一种蛋白质受体，像探棒一样从工程化的T细胞中伸出。CAR的癌细胞检测端通常 源自抗体分子的抗原结合片段，能以极高的特异性抓取任何靶点。与以往可控CAR设计不同，新系统 仅使用人类蛋白成分和临床认可的非免疫抑制药物，直接破坏CAR-T细胞与肿瘤细胞的结合。由于该开 ...

证 券 研 究 报 告 资料来源：公司公告，华创证券预测 注：股价为 2026 年 2 月 23 日收盘价 港股公司 生物医药Ⅲ 2026 年 02 月 24 日 目标价：11.26 港元 当前价：6.37 港元 华创证券研究所 证券分析师：刘浩 邮箱：liuhao@hcyjs.com 执业编号：S0360520120002 加科思-B（01167.HK）深度研究报告 强推（首次） pan-KRAS 抑制剂价值重估空间大 [主要财务指标 Indicator_FinchinaSimpleHK] | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万元) | 156 | 234 | 627 | 508 | | 同比增速(%) | 145.1% | 50.5% | 167.6% | -19.1% | | 归母净利润(百万元) | -156 | -15 | 313 | 192 | | 同比增速(%) | 56.6% | 90.7% | 2,258.6% | -38.6% | | 每股盈利(元) | -0.20 | - ...

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任 何投资建议。 | 肿瘤/肿瘤免疫 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 项目 (合作方) | 靶点 | 适应症 | 地区 | 早期发现 | 临床前 | IND | 一期 | 二期 | 三期 | BLA | | 新一代免疫肿瘤治疗单抗 | | | | | | | | | | | | Porustobart (HBM4003) | CTLA-4 | ◆ 黑色素瘤 | 全球 | | | | | | | | | | | ◆ 结直肠癌 | 全球 | | | | | | | | | | | ◆ 肝细胞癌 | 全球 | | | | | | | | | | | ◆ 神经内分泌癌 | 全球 | | | | | | | | | *. | | | | | | | | | | | 药融圈监测显示：和铂医药与海外初创新药公司Solstice Oncology ...

经济观察网 基于截至2026年2月的最新公开信息，宜明昂科-B（股票代码：01541.HK）有以下值得关注 的事件进展，主要涉及核心产品研发、监管申请及合作动态。以下内容均来自公司公告及媒体报道，按 时间顺序和重要性梳理。 产品研发进展 III期临床试验中期分析：公司核心产品IMM01（替达派西普）用于慢性粒-单核细胞白血病（CMML） 一线治疗的III期临床试验，已于2025年12月31日完成104例患者招募，预计在2026年3月底前完成中期分 析所需的132例患者招募。中期分析数据将用于评估完全缓解率（CR率），为后续申请奠定基础。 合作调整与资产回收：2026年1月，公司终止与Instil Bio子公司Axion Bio的许可协议，收回IMM2510 （PD-L1xVEGF双抗）和IMM27M（CTLA-4抗体）的全球权利，并保留已收到的3500万美元付款。创 始人田文志表示，公司正与多家跨国药企接触，计划在2026年寻求新的合作伙伴以推进全球化开发。 公司状况 公司治理事件：2026年2月10日，公司向创始人田文志提供了一笔本金为1372.47万元人民币的贷款，公 告称此举基于公司财务状况良好，且不会 ...

编辑丨王多鱼 排版丨水成文 在肿瘤的发生发展过程中，抗原特异性 CD8 ⁺ T 细胞 的命运与功能分化，直接决定了免疫系统能否有效控 制肿瘤。在肿瘤微环境内，CD8 ⁺ T 细胞主要分化为两个关键亚群：具有自我更新和增殖潜能的 前体耗竭 T 细胞 （Tpex） ，以及具备强大即时杀伤能力但增殖受限的 终末耗竭 T 细胞 （Ttex） 。Tpex 细胞是响 应免疫检查点阻断治疗的"种子"细胞，而 Ttex 细胞则是直接攻击肿瘤的"主力军"。 然而，究竟是哪些关键因子在幕后推动并维持该细胞的分化与功能，这一直是肿瘤免疫领域的核心谜团。 202 6 年 2 月 6 日 ， 西湖大学 董晨 院士团队 （ 清华大学免疫研究所博士生 潘必睿 为该论文的第一作 者 ） 在 Journal of Experimental Medicine 期刊发表了题为 ： Zbtb32 promotes CD8 ⁺ T cell differentiation and function in cancer 的研究论文。 该研究 首次系统鉴定出转录因子 Zbtb32 是驱动 CD8 ⁺ T 细胞向 终末耗竭状态 分化并增强其抗肿瘤功能 的核 ...

Core Viewpoint - Pfizer has unveiled a significant R&D plan for 707/PF'4404 (PD-1/VEGF) in collaboration with 3SBio, with an accelerated pace and breadth beyond expectations, aiming to initiate four global Phase III clinical trials by 2026 across five major first-line indications [1][2] Group 1: Clinical Development - Pfizer plans to launch four Phase III clinical trials in 2026 targeting first-line squamous/non-squamous NSCLC, mCRC, endometrial cancer, and urothelial carcinoma [2] - The company has already completed the first patient enrollment for Phase III trials targeting first-line NSCLC and mCRC, as well as Phase II/III trials for first-line ES-SCLC [2] - Pfizer will also initiate Phase III clinical studies combining 707 with various ADCs, such as Padcev for first-line treatment of urothelial carcinoma [2] Group 2: Competitive Landscape - Four multinational corporations (MNCs) are competing in the PD-(L)1/VEGF space, including Pfizer, BMS, Merck, and AbbVie, with Pfizer expected to stand out due to its "speed, breadth, and depth" advantages [2] - BMS and BioNTech have announced extensive clinical plans, but their progress in core indications like first-line NSCLC and mCRC lags behind Pfizer [2] Group 3: Pipeline and Financials - 3SBio is increasing R&D investments with multiple pipelines expected to yield clinical data, including 705 (PD-1/HER2) and 706 (PD-1/PD-L1) in Phase II trials in China [3] - The core business fundamentals of 3SBio remain robust, with projected revenue of approximately 4.2 billion yuan in 2025, including 2.89 billion yuan from the upfront payment for 707 licensing [3] - Excluding the upfront payment, the internal business revenue of 3SBio is estimated to grow by about 9% year-on-year [3] Group 4: Investment Rating - The company maintains a "Buy" rating with a target price of 37.43 HKD, supported by an estimated net cash position of approximately 13 billion yuan [4] - Confidence in 707 becoming a global blockbuster is reaffirmed due to Pfizer's unexpected clinical advancement [4]

Group 1: Market Overview - The Hang Seng Index closed at 27,127, up 1.35% for the day and 5.84% year-to-date [1] - The Hang Seng Financial Index rose by 2.51% for the day and 5.88% year-to-date, indicating strong performance in the financial sector [2] - Southbound capital recorded a net sell of 635 million HKD, with notable sell-offs in China Mobile, Zijin Mining, and SMIC, while Tencent and Longi Green Energy saw significant net buying [3] Group 2: Company Analysis - Sanofi - Sanofi's collaboration with Pfizer on the 707/PF'4404 (PD-1/VEGF) has advanced rapidly, with plans to initiate four global Phase III clinical trials by 2026 covering five major indications [4] - The dual antibody PD-(L)1/VEGF is expected to become a cornerstone in next-generation tumor immunotherapy, with Sanofi leveraging its internal pipeline for competitive advantage [5] - Sanofi's robust pipeline includes multiple candidates, with the potential for early assets to be licensed out as clinical data matures [6] Group 3: Financial Projections - The target price for Sanofi is set at 37.43 HKD, based on a DCF model with a WACC of 10.11% and a perpetual growth rate of 2.0% [7] - The company is estimated to have net cash of approximately 13 billion HKD, supporting its growth and development initiatives [7]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 37.43, representing a potential upside of 55.5% from the current price of HKD 24.08 [2][8]. Core Insights - Pfizer is rapidly advancing the global clinical development of 707/PF'4404 (PD-1/VEGF), with plans to initiate four global Phase III trials in 2026 targeting five major indications. The combination of PD-(L)1/VEGF dual antibodies is expected to become a cornerstone of next-generation cancer immunotherapy, positioning Pfizer to leverage its internal pipeline synergy and strong clinical execution capabilities [1][8]. - The company is increasing its R&D investments, with several pipelines expected to yield clinical data soon. The core business fundamentals remain robust, providing a safety margin, and the company is projected to achieve significant revenue growth driven by its innovative pipeline [8][12]. Financial Summary - For FY23A, the company reported sales revenue of RMB 7,816 million, with a year-on-year growth of 13.8%. The projected sales revenue for FY25E is RMB 17,972 million, reflecting a substantial increase of 97.3% [2][15]. - The net profit attributable to shareholders for FY23A was RMB 1,549 million, with a year-on-year decline of 19.1%. However, the forecast for FY25E shows a significant increase to RMB 9,741 million, indicating a growth of 366.0% [2][15]. - The earnings per share (EPS) for FY23A was RMB 0.64, expected to rise to RMB 3.84 in FY25E [2][15]. Market Position and Shareholder Structure - The company's market capitalization is approximately HKD 61,115.2 million, with a 52-week stock price range of HKD 35.90 to HKD 6.01 [3][4]. - Major shareholders include TMF (Cayman) Ltd. with 22.8% and Decade Sunshine with 19.6% [4]. Clinical Development and Pipeline - The report highlights the competitive landscape for PD-(L)1/VEGF therapies, with Pfizer's strategy of combining IO with ADCs as a unique advantage. The company plans to conduct multiple Phase III trials for various indications, including NSCLC and mCRC, with a focus on rapid patient recruitment [1][8]. - The ongoing clinical trials for other innovative products, such as 705 (PD-1/HER2) and 706 (PD-1/PD-L1), are also expected to contribute to the company's growth and potential licensing opportunities [8][12].

Core Viewpoint - XinNuoWei (300765.SZ) announced that its subsidiary, Giant Stone Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SYS6090 injection, which will commence shortly [1] Group 1: Product Details - SYS6090 injection is a recombinant fully human anti-PD-1 fusion protein with IL-15, designed as an asymmetric structure dual-functional Fc, which aims to weaken Fc-mediated immune functions [1] - The left arm of SYS6090 targets PD-1 positive tumor-infiltrating immune cells to block the immunosuppressive interaction between PD-1 and PD-L1 [1] - The right arm binds to the IL-15 receptor, activating downstream signaling pathways to further promote the activation and proliferation of relevant immune cells [1] Group 2: Preclinical Research Findings - Preclinical studies have shown that SYS6090 injection significantly inhibits tumor growth and demonstrates good safety and tolerability [1] - Compared to other PD-1 monoclonal antibodies and IL-15 drugs, SYS6090 exhibits higher efficacy [1]